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The COVID-19 pandemic has served as a stress test for
communities made vulnerable by racism, bias, geography,
disability, and socioeconomic status. Science and innova-
tion are central to any solutions that enable communities to
overcome a failed stress test and barriers to health parity.
OperationWarp Speed and scientific advancements have led
to the development of COVID-19 vaccines in an unprece-
dented time-frame; however, the project’s name and speed
of the clinical trial process have resulted in some skepticism
about vaccine safety and effectiveness. According to the
Kaiser Family Foundation (KFF) vaccine monitor, the
willingness of the Black community to receive a COVID-19
vaccine has improved from 50% in September to 62% in
December. Although, 35% of Black people surveyed re-
ported unwillingness to receive the vaccine in December,
which is the highest rate among racial/ethnic groups. The
importance of the KFF findings are magnified when juxta-
posedwith theBlack communityCOVID-19 hospitalization
rate of nearly 4 times greater and a death rate of nearly 3
times greater than the White community.1,2 Furthermore,
29% of healthcare workers reported unwillingness to
receive COVID-19 vaccination in December.1
Serving in our role as trusted messengers in the Black
community and a leading voice for health parity, a resolution
to establish a COVID-19 Task Force on Vaccines and Ther-
apeuticswas introducedbyRodneyG.Hood,MD,NMAPast
President and delegate from California, and Jennifer R.
Walton, MD, MPH, Chair Pediatric Section and delegate
from Ohio, that was unanimously passed by the House of
Delegates onAugust 4, 2020.Members of the task forcewere6 VOL. 113, NO 1, FEBRUARY 2021appointed by President Leon McDougle, MD,MPH, (Chair)
and include Patricia N. Whitley-Williams, MD, pediatric in-
fectious disease specialist; Dial Hewlett, Jr,MD, andVirginia
A. Caine, MD, who are both infectious disease specialist;
Sonja S. Hutchins, MD, MPH, DrPh, community medicine
and preventive health specialist; LakeshaM.Butler, PharmD,
BCPS, immediate-past President of the National Pharma-
ceutical Association; Khadijah Lang, MD, family medicine
physician; Oliver T. Brooks, MD, immediate-past President
of theNMA,pediatric and adolescentmedicine specialist; and
Rodney Hood, MD, internist. The Task Force was charged
with advisingNMAmembers, healthcare partners and patient
constituents about the safety and efficacy of COVID-19
vaccines and treatments.
Since October of 2020 the task force has been meeting
with Pfizer-BioNTech and Moderna clinical scientist and
reviewing clinical trial outcomes data made available to the
United States Food and Drug Administration (FDA) and the
CDC ACIP concerning the messenger RNA vaccines.
The task force reviewed the clinical trial data in search of
differences in health outcomes that would place the Black
community at higher risk of unfavorable outcomes from the
vaccine. It was determined that the number and percentage
of Black people enrolled in the Pfizer-BioNTech and
Moderna phase 3 clinical trials were sufficient to haveJOURNAL OF THE NATIONAL MEDICAL ASSOCIATION
TRUSTED MESSENGERS: COVID-19 VACCINESconfidence in the health outcomes. Ten percent of partici-
pants in both clinical trials were Black equaling more than
4400 and 3000 people, respectively. Persons receiving the
vaccine were >94% less likely to develop COVID-19
infection as compared to the placebo group. Efficacy and
safety were observed and consistent across race, ethnicity,
gender, and age including adults over 65 years of age.
When comparing the outcomes of people receiving the
vaccine versus the placebo injection there were no signifi-
cant differences in the occurrence of SeriousAdverseEvents
(SAE). In England, two people with a prior history of severe
allergies developed anaphylaxis immediately after receiving
the Pfizer-BioNTech vaccine outside of the clinical trial.
They did recover from the allergic reaction. While these
reports are being investigated, caution should be observed
for any person with history of severe allergy to vaccines or
other injectable therapy. Patients with a severe allergic re-
action (anaphylaxis) to the vaccine components have a
contraindication to receiving these vaccines. Please refer to
the CDC ACIP recommendations for more details.3e6
Themessenger RNAvaccines cannot transmit COVID-19
infection. These vaccines enable the immune system to
develop antibodies to a segment of the coronavirus called the
spike protein. Immunity should be achieved about 7e14 days
following the 2nd dose of the vaccine. Short-term symptoms
are commonly experienced following the Pfizer-BioNTech
and Moderna vaccinations and last an average of 1e3 days
and include pain and redness at injection site, fatigue, muscle
aches and pains, joint pain and headache.
The task force review also included questions about
safety of vaccine administration in special populations,
such as persons with sickle cell disease or sickle cell trait,
autoimmune diseases like systemic lupus erythematosus,
and HIV that disproportionately impact Black populations.
In general, persons with chronic diseases that are
controlled, and stable do qualify for receiving the vaccines.
Consultation with one’s healthcare provider beforehand is
advisable. A request for analysis of data for participants
with sickle cell disease or sickle cell trait was submitted by
the NMA COVID-19 Task Force and is pending. Partici-
pants with controlled autoimmune diseases were enrolled
in the clinical trials and an increased risk to receiving the
vaccines was not observed. Participants with controlled
HIV with CD4 counts of more than 200 and undetectable
viral load were enrolled in the clinical trials. Data will be
reported during or before the 1st quarter of 2021 with the
Biologics License Applications.
In addition, reproductive toxicology studies in animals
did not reveal increased risk of vaccines to the fetus during
pregnancy. Expanding clinical trial enrollment to include
pregnant women is planned along with descending
enrollment ages to include adolescents and children. TheJOURNAL OF THE NATIONAL MEDICAL ASSOCIATIONTask Force is supportive of post-licensure surveillance
plans including the Vaccine Adverse Event Reporting
System https://vaers.hhs.gov/and V-safe https://www.cdc.
gov/to monitor for Serious Adverse Events in persons
who receive the vaccines and inform precautions as needed
for future vaccine administration. The planned 2-year
Phase 4 follow-up of clinical trial participants was also
thought to be important.
CONCLUSION
The U.S. FDA approval for emergency use authorization
(EUA) of the Pfizer-BioNTech and Moderna vaccines is
supported by findings of the NMA COVID-19 Task Force
on Vaccines and Therapeutics. In addition, emphasis must
also be placed on building parity into dissemination plans
for the vaccines that include culturally sensitive, multi-
lingual outreach tailored for local communities to help
decrease vaccination hesitancy and close gaps in health
outcomes.REFERENCES
1. Hamel, L., et al. (2020). Kaiser family foundation vaccine
monitor: December 2020. https://www.kff.org/coronavirus-
covid-19/report/kff-covid-19-vaccine-monitor-december-2020/.
2. COVID-19 hospitalization and death by race/ethnicity. National
center for immunization and respiratory diseases (NCIRD), division
of viral diseases. https://www.cdc.gov/coronavirus/2019-ncov/
covid-data/investigations-discovery/hospitalization-death-by-
race-ethnicity.html, (2020).
3. Interim clinical considerations for use ofmRNACOVID-19 vaccines
currently authorized in the United States. National center for im-
munization and respiratory diseases (NCIRD). https://www.cdc.
gov/vaccines/covid-19/info-by-product/clinical-considerations.
html, (2020).
4. Interim considerations: preparing for the potential manage-
ment of anaphylaxis after COVID-19 vaccination. National
Center for Immunization and Respiratory Diseases (NCIRD).
https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/
anaphylaxis-management.html, (2020).
5. Oliver, S. E., et al. (2020). The advisory committee on immuni-
zation practices’ interim recommendation for use of pfizer-
BioNTech COVID-19 vaccine d United States, December 2020.
MMWR Morb Mortal Wkly Rep, 69(50), 1922e1924. https://www.
cdc.gov/mmwr/volumes/69/wr/mm6950e2.htm?s_cid¼mm695
0e2_x.
6. Oliver, S. E., et al. (2020). The advisory committee on immuni-
zation practices’ interim recommendation for use of Moderna
COVID-19 vaccine d United States. MMWR Morb Mortal Wkly
Rep, 69, 1653e1656. https://www.cdc.gov/mmwr/volumes/69/
wr/mm695152e1.htm?s_cid¼mm695152e1.VOL 113, NO 1, FEBRUARY 2021 7
 
 
Since January 2020 Elsevier has created a COVID-19 resource centre with 
free information in English and Mandarin on the novel coronavirus COVID-
19. The COVID-19 resource centre is hosted on Elsevier Connect, the 
company's public news and information website. 
 
Elsevier hereby grants permission to make all its COVID-19-related 
research that is available on the COVID-19 resource centre - including this 
research content - immediately available in PubMed Central and other 
publicly funded repositories, such as the WHO COVID database with rights 
for unrestricted research re-use and analyses in any form or by any means 
with acknowledgement of the original source. These permissions are 
granted for free by Elsevier for as long as the COVID-19 resource centre 
remains active. 
 
